BIOLASE, Inc.
BIOL · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -185.53% | -21.14% | -171.48% | -72.70% |
| EV / EBITDA | -25.44 | -8.41 | -3.80 | -3.34 |
| Quality | ||||
| ROIC | -4.72% | -23.77% | -27.30% | -27.23% |
| Gross Margin | 40.39% | 39.89% | 32.93% | 26.12% |
| Cash Conversion Ratio | 3.13 | 0.26 | 0.92 | 0.43 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.57% | 1.30% | 5.79% | 7.85% |
| Free Cash Flow Growth | -492.90% | 87.13% | -139.51% | 10.90% |
| Safety | ||||
| Net Debt / EBITDA | -21.94 | -6.08 | -2.91 | -2.57 |
| Interest Coverage | -1.15 | -5.49 | -7.28 | -8.42 |
| Efficiency | ||||
| Inventory Turnover | 0.66 | 0.64 | 0.60 | 0.87 |
| Cash Conversion Cycle | 124.86 | 107.85 | 134.73 | 85.06 |